Mechanisms of Acquired Resistance to AZD9291-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Mechanisms of Acquired Resistance to AZD9291

Published:2015-12 Issue:12 Volume:10 Page:1736-1744
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Kim Tae Min,Song Ahnah,Kim Dong-Wan,Kim Soyeon,Ahn Yong-Oon,Keam Bhumsuk,Jeon Yoon Kyung,Lee Se-Hoon,Chung Doo Hyun,Heo Dae Seog

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference37 articles.

1. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways;Sordella;Science,2004

2. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib;Lynch;N Engl J Med,2004

3. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy;Paez;Science,2004

4. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med,2009

5. The quest to overcome resistance to EGFR-targeted therapies in cancer;Chong;Nat Med,2013

Cited by 196 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies;MedComm;2024-08-24

2. Non-small cell lung cancer: an update on emerging EGFR-targeted therapies;Expert Opinion on Emerging Drugs;2024-04-02

3. The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open for new therapeutic strategies;Critical Reviews in Oncology/Hematology;2024-04

4. Design, Synthesis, and Biological Evaluation of Dual Inhibitors of EGFR^L858R/T790M/ACK1 to Overcome Osimertinib Resistance in Nonsmall Cell Lung Cancers;Journal of Medicinal Chemistry;2024-02-07

5. Modification of osimertinib to discover new potent EGFRC797S-TK inhibitors;European Journal of Medicinal Chemistry;2023-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3